|Title:||Phenidate drug formulations having diminished abuse potential|
|Abstract:||Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.|
|Inventor(s):||Zeitlin; Andrew L. (Millington, NJ), Dariani; Maghsoud M. (Fanwood, NJ)|
|Assignee:||Celgene Corporation (Warren, NJ)|
1. A pharmaceutical unit dosage comprising from about 1 to about 50 milligrams of D-threo-methylphenidate or a pharmaceutically acceptable salt thereof said dosage having less
than 10% by weight of other stereoisomers of methylphenidate or the salt thereof.
2. The unit dosage of claim 1 comprising from about 2 to about 20 milligrams of D-threo-methylphenidate.
3. The unit dosage of claim 1 comprising from about 21/2 to about 12 milligrams of D-threo-methylphenidate.
4. The unit dosage of claim 1 in a form suitable for oral administration.